Investors in Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Face Lawsuit

Investors in Sage Therapeutics, Inc. (NASDAQ:SAGE) are facing a pending lawsuit over alleged securities laws violations. The lawsuit, filed on August 28, 2024, claims that the company made false and misleading statements regarding the effectiveness of zuranolone in treating Major Depressive Disorder (MDD), SAGE-718 in treating Mild Cognitive Impairment (MCI) due to Parkinson’s Disease (PD), and SAGE-324 in treating Essential Tremor (ET).

The plaintiff alleges that the company overstated the clinical results and regulatory prospects of these drugs, leading investors to believe in their potential success. As a result, the company’s public statements were deemed materially false and misleading.

Investors who purchased shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) are urged to contact the Shareholders Foundation, Inc. for more information on their options. The Shareholders Foundation is a professional portfolio legal monitoring and settlement claim filing service that provides research on shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal news related to the stock market.

For more information, investors can contact Michael Daniels at mail@shareholdersfoundation.com or call +1 (858) 779-1554. Stay informed and protect your investments with the Shareholders Foundation, Inc.

Source: Shareholders Foundation, Inc.